Latest Acute myeloid leukemia Stories
Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).
- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb.
-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb.
Analyzing the genomes of twin 3-year-old sisters – one healthy and one with aggressive leukemia – led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies.
SAN DIEGO, Feb.
FT. MYERS, Fla., Jan. 30, 2014 /PRNewswire/ -- NeoGenomics, Inc.
- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc.
In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML).
SAN DIEGO, Jan.
- The act of sweetening by admixture of some saccharine substance.